Captor Therapeutics Spolka Akcyjna (CTX.WA)
PLN 47.8
(5.99%)
PLN 47.8
(5.99%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.9 Million PLN | -72.76% |
| 2022 | 7.07 Million PLN | 117.9% |
| 2021 | 3.24 Million PLN | 149.15% |
| 2020 | -6.6 Million PLN | -48.09% |
| 2019 | -4.45 Million PLN | -73.46% |
| 2018 | -2.57 Million PLN | -778.1% |
| 2017 | 379 Thousand PLN | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.98 Million PLN | 100.0% |
| 2024 Q2 | 2.33 Million PLN | 15.05% |
| 2023 Q4 | 1.49 Million PLN | 41.56% |
| 2023 Q1 | 1.11 Million PLN | -77.17% |
| 2023 Q3 | 1.05 Million PLN | -58.19% |
| 2023 FY | 1.92 Million PLN | -72.76% |
| 2023 Q2 | 2.52 Million PLN | 127.12% |
| 2022 Q2 | 888 Thousand PLN | 17.77% |
| 2022 FY | 7.07 Million PLN | 117.9% |
| 2022 Q4 | 4.86 Million PLN | 759.19% |
| 2022 Q3 | 566 Thousand PLN | -36.26% |
| 2022 Q1 | 754 Thousand PLN | -26.08% |
| 2021 Q2 | 1.03 Million PLN | 142.92% |
| 2021 Q4 | 1.02 Million PLN | 32.3% |
| 2021 Q3 | 771 Thousand PLN | -25.15% |
| 2021 FY | 3.24 Million PLN | 149.15% |
| 2021 Q1 | 424 Thousand PLN | 0.0% |
| 2020 FY | -6.6 Million PLN | -48.09% |
| 2020 Q3 | -7000.00 PLN | 0.0% |
| 2020 Q4 | - PLN | 100.0% |
| 2019 FY | -4.45 Million PLN | -73.46% |
| 2018 FY | -2.57 Million PLN | -778.1% |
| 2017 FY | 379 Thousand PLN | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioceltix S.A. | -1.03 Million PLN | 764.788% |
| BIOTON S.A. | 72.85 Million PLN | 90.528% |
| Mabion S.A. | 114.58 Million PLN | 93.977% |
| Molecure S.A. | -4.1 Million PLN | 268.251% |
| NanoGroup S.A. | -79.01 Thousand PLN | 8833.564% |
| Pharmena S.A. | 5.84 Million PLN | -18.107% |
| Poltreg S.A. | -1.38 Million PLN | 597.549% |
| Pure Biologics Spólka Akcyjna | -2.57 Million PLN | 368.104% |
| Ryvu Therapeutics S.A. | 29.3 Million PLN | 76.452% |
| Synthaverse S.A. | 35.16 Million PLN | 80.376% |
| Urteste S.A. | -479 Thousand PLN | 1540.71% |